Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06534411 · ClinicalTrials.gov registry record · Phase 3

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both

A Phase 3 study of Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S.

Active
Registry status
Phase 3
Development phase
1,023
Enrollment target
20
Study locations

NCT06534411: Active Phase 3 study of Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S.

NCT06534411 is a Phase 3 study of Diabetes Mellitus, Type 2 that is active but no longer recruiting, run by Novo Nordisk A/S. The registered enrollment target is 1,023 participants, below the 4,482-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (77% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06534411, a Phase 3 study of Diabetes Mellitus, Type 2, is active but no longer recruiting, sponsored by Novo Nordisk A/S.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
1,023 participants
Enrollment target
20
Study locations

Study Summary

This study will look at how much CagriSema lowers blood sugar and body weight in people with type 2 diabetes. CagriSema is a new investigational medicine. Doctors cannot yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide. Doctors can prescribe tirzepatide in some countries. Participants will either receive CagriSema or tirzepatide. Which treatment the participant will receive is decided by chance. For each participant, the study will last for up to 1 year and 4 months.

Primary Outcome

Measured in percentage points.

Conditions Studied

Diabetes Mellitus, Type 2

Interventions

  • DRUG Tirzepatide
  • DRUG Semaglutide
  • DRUG Cagrilintide

Study Locations (20)

California

  • Velocity Clin Res-Chula Vista - Chula Vista
  • John Muir Physicians Network - Concord
  • Diabetes & Endocrine Specialists - La Mesa - La Mesa
  • Velocity Clin Research LA - Los Angeles
  • Desert Oasis Healthcare - Palm Springs
  • Velocity Clin Res Santa Ana - Santa Ana
  • Velocity Clin Res - Panorama - Van Nuys

Florida

  • Tampa Bay Medical Research - Clearwater
  • AGA Clinical Trial - Hialeah
  • Clinical Trial Services Corp - Miami
  • Bioclinical Research Alliance - Miami
  • New Horizon Research Center - Miami
  • South Broward Research LLC - Miramar
  • West Orange Endocrinology - Ocoee

Arizona

  • Velocity Clinical Research-Phoenix - Phoenix
  • AES Tucson DRS - Tucson

Alabama

  • Cahaba Research - Pelham

Arkansas

  • Woodland Int. Research Group - Little Rock

Colorado

  • Optumcare Clinical Trials,LLC-Golden - Colorado Springs

District of Columbia

  • FEME Medical LLC - Washington D.C.

Trial Details

FieldValue
Enrollment Target 1,023 participants
Start Date 2024-11-05
Est. Completion 2026-07-14
Phase Phase 3
Novo Nordisk A/S

431 total trials

What the registry record for NCT06534411 still lists

NCT06534411 is an interventional study that assigns participants to a tested intervention. Its 1,023 participants enrollment target places it among the larger protocols in the corpus, below the 4,482-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (77% lower).

The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 3 interventions - of which Tirzepatide is the first listed.

NCT06534411 names 20 study sites across 7 states, led by California, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT06534411 about?

NCT06534411 is a clinical study titled "A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both". This study will look at how much CagriSema lowers blood sugar and body weight in people with type 2 diabetes. CagriSema is a new investigational medicine. Doctors cannot yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide. Doctors can prescribe tirzepatide in some co...

What is the current status of trial NCT06534411?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,023 participants. The study started on 2024-11-05. Estimated completion is 2026-07-14.

What conditions does trial NCT06534411 study?

This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.

What interventions are being tested in trial NCT06534411?

The interventions under investigation include: Tirzepatide (DRUG), Semaglutide (DRUG), Cagrilintide (DRUG).

Who is sponsoring clinical trial NCT06534411?

This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06534411 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diabetes Mellitus, Type 2

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06534411's enrollment target sits among peer trials

1,023 34th of 348 higher than 315 of 348 other Diabetes Mellitus, Type 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT07216703 · 1,023 participants · Phase 3

    A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

  • NCT06888011 · 1,024 participants · NA

    iAmHealthy Clinical Practice Guideline (CPG)

  • NCT02200276 · 1,025 participants · NA

    Influenza Immunization in Adults Over Age 75

  • NCT02296450 · 1,025 participants

    Quality of Life (QoL) Assessment in Cancer Patients and Survivors With Dermatologic Conditions Using Dermatologic QoL Instruments

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT06534411, the US trial registry maintained by the National Library of Medicine. NCT06534411 (large enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.